{"id":"ckd-11101","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited public information is available regarding the specific mechanism of action for CKD-11101. As a phase 3 candidate from a South Korean pharmaceutical company, it is likely a small molecule or biologic targeting a specific disease pathway, but the exact molecular target and therapeutic mechanism require access to clinical trial data or company disclosures.","oneSentence":"CKD-11101 is a novel therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical with a mechanism not yet publicly disclosed.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:06:09.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03431623","phase":"PHASE3","title":"CKD-11101 Phase 3 SC Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-05","conditions":"Anemia of Chronic Kidney Disease","enrollment":248},{"nctId":"NCT03428594","phase":"PHASE3","title":"CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-06","conditions":"Anemia of Chronic Kidney Disease","enrollment":403},{"nctId":"NCT01685671","phase":"PHASE1","title":"Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-10-26","conditions":"Anemia","enrollment":34},{"nctId":"NCT01684605","phase":"PHASE1","title":"Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-10-12","conditions":"Anemia","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CKD-11101","genericName":"CKD-11101","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}